 |
|
Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Sylvia K. Plevritis, PhD;
Allison W. Kurian, MD;
Bronislava M. Sigal, PhD;
Bruce L. Daniel, MD;
Debra M. Ikeda, MD;
Frank E. Stockdale, MD, PhD;
Alan M. Garber, MD, PhD
JAMA. 2006;295:2374-2384.
Context Women with inherited BRCA1/2 mutations are at high risk for breast cancer, which mammography often misses. Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans.
Objective To evaluate the cost-effectiveness of screening BRCA1/2 mutation carriers with mammography plus breast MRI compared with mammography alone.
Design, Setting, and Patients A computer model that simulates the life histories of individual BRCA1/2 mutation carriers, incorporating the effects of mammographic and MRI screening was used. The accuracy of mammography and breast MRI was estimated from published data in high-risk women. Breast cancer survival in the absence of screening was based on the Surveillance, Epidemiology and End Results database of breast cancer patients diagnosed in the prescreening period (1975-1981), adjusted for the current use of adjuvant therapy. Utilization rates and costs of diagnostic and treatment interventions were based on a combination of published literature and Medicare payments for 2005.
Main Outcome Measures The survival benefit, incremental costs, and cost-effectiveness of MRI screening strategies, which varied by ages of starting and stopping MRI screening, were computed separately for BRCA1 and BRCA2 mutation carriers.
Results Screening strategies that incorporate annual MRI as well as annual mammography have a cost per quality-adjusted life-year (QALY) gained ranging from less than $45 000 to more than $700 000, depending on the ages selected for MRI screening and the specific BRCA mutation. Relative to screening with mammography alone, the cost per QALY gained by adding MRI from ages 35 to 54 years is $55 420 for BRCA1 mutation carriers, $130 695 for BRCA2 mutation carriers, and $98 454 for BRCA2 mutation carriers who have mammographically dense breasts.
Conclusions Breast MRI screening is more cost-effective for BRCA1 than BRCA2 mutation carriers. The cost-effectiveness of adding MRI to mammography varies greatly by age.
Author Affiliations: Departments of Radiology (Drs Plevritis, Sigal, Daniel, and Ikeda) and Medicine (Drs Kurian and Stockdale), Division of Oncology, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, Calif; and VA Palo Alto Health Care System, Palo Alto, Calif (Dr Garber).
RELATED LETTERS
Cost-effectiveness of Breast Magnetic Resonance Imaging to Screen BRCA1/2 Mutation Carriers
Pavel Crystal
JAMA. 2006;296(22):2681-2682.
EXTRACT
| FULL TEXT
Cost-effectiveness of Breast Magnetic Resonance Imaging to Screen BRCA1/2 Mutation Carriers—Reply
Sylvia K. Plevritis, Debra M. Ikeda, and Alan M. Garber
JAMA. 2006;296(22):2682.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
Shih and Halpern
CA Cancer J Clin 2008;58:231-244.
ABSTRACT
| FULL TEXT
Breast Cancer Screening in BRCA1 Mutation Carriers: Effectiveness of MR Imaging--Markov Monte Carlo Decision Analysis
Lee et al.
Radiology 2008;246:763-771.
ABSTRACT
| FULL TEXT
Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review
BERMEJO-PEREZ et al.
Br. J. Radiol. 2008;81:172-179.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Digital Mammography Breast Cancer Screening
Tosteson et al.
ANN INTERN MED 2008;148:1-10.
ABSTRACT
| FULL TEXT
Screening and Follow-up of the Patient at High Risk for Breast Cancer
Willey and Cocilovo
Obstet Gynecol 2007;110:1404-1416.
ABSTRACT
| FULL TEXT
Current Status of Breast MR Imaging * Part 2. Clinical Applications
Kuhl
Radiology 2007;244:672-691.
ABSTRACT
| FULL TEXT
Management of an Inherited Predisposition to Breast Cancer
Robson and Offit
NEJM 2007;357:154-162.
FULL TEXT
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch et al.
Ann Oncol 2007;18:1133-1144.
ABSTRACT
| FULL TEXT
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow et al.
CA Cancer J Clin 2007;57:75-89.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Breast Magnetic Resonance Imaging to Screen BRCA1/2 Mutation Carriers
Crystal
JAMA 2006;296:2681-2682.
FULL TEXT
What's new in the other general journals.
Tonks
BMJ 2006;332:1327-1327.
FULL TEXT
|
